| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
|
Medicine details |
|
| Medicine name | caplacizumab (Cablivi®) |
| Formulation | 10 mg powder and solvent for solution for injection |
| Reference number | 4585 |
| Indication | Treatment of adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression |
| Company | Sanofi |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/07/2020 |
| NICE guidance | |